China Diabetes Drugs Market Report 2022 to2030

China Diabetes Drugs Market Analysis

$ 3999

The China diabetes drugs market size was valued at $4.96 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.6% from 2022 to 2030 and will reach $8.9 Bn in 2030. The market is segmented by drug type, application, and distribution channel. The China diabetes drug market will grow because China is the country with the largest population of people with diabetes in the world. The key market players are Gan & Lee Pharmaceuticals (CHN), Tonghua Dongbao Pharmaceutical (CHN), Jiangsu Hengrui Medicine (CHN), and others.

ID: IN10CNPH009 CATEGORY: Pharmaceuticals GEOGRAPHY: China AUTHOR: Chandani Patel

Buy Now

China Diabetes Drugs Market Executive Summary

The China diabetes drugs market size was valued at $4.96 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.6% from 2022 to 2030 and will reach $8.9 Bn in 2030. China's healthcare expenditure has been steadily increasing in recent years. According to the National Bureau of Statistics of China, healthcare expenditure in China reached $1.3 trillion in 2020, accounting for 6.9% of the country's GDP. This represents a significant increase from just 4.7% of GDP in 2009. One of the main factors driving the increase in healthcare expenditure in China is the aging population. With an increasing number of elderly people in the country, there is greater demand for healthcare services and higher healthcare costs. In addition, the government has been increasing its investment in healthcare, with a focus on improving access to healthcare services and increasing health insurance coverage.

According to the International Diabetes Federation (IDF), China has the largest number of people with diabetes in the world, with an estimated 116 Mn adults aged 20-79 years living with the disease in 2021. The prevalence of diabetes in China is also increasing rapidly due to changing lifestyles, urbanization, and an aging population.

The high prevalence of diabetes in China has led to significant demand for diabetes drugs in the country. The diabetes drug market in China is expected to grow rapidly in the coming years, driven by the increasing prevalence of diabetes and the government's efforts to improve healthcare access and affordability. The Chinese government has taken several steps to address the diabetes epidemic in the country, including launching a national diabetes prevention and treatment program and implementing policies to promote healthy lifestyles and prevent diabetes-related complications.

In addition, multinational pharmaceutical companies have also been increasing their presence in the Chinese market and developing new diabetes drugs to meet the growing demand. Local pharmaceutical companies have also been investing in research and development to develop innovative diabetes treatments. The high prevalence of diabetes in China has had a significant impact on the diabetes drug market in the country, leading to increased demand for diabetes drugs and investment in research and development by both local and multinational pharmaceutical companies.

china diabetes drugs market

Market Dynamics

Market Growth Drivers Analysis

China is the country with the largest population of people with diabetes in the world, which has led to significant demand for diabetes drugs in the country. The diabetes drugs market in China is expected to grow rapidly in the coming years, driven by several factors.

One of the main drivers of the diabetes drugs market in China is the increasing prevalence of diabetes. This is due to changing lifestyles, urbanization, and an aging population, all of which have contributed to the rise in diabetes cases in the country. As a result, there is a growing demand for diabetes drugs in China, which is driving the growth of the market.

Another driver of the diabetes drugs market in China is the government's efforts to improve healthcare access and affordability. The Chinese government has launched a national diabetes prevention and treatment program and implemented policies to promote healthy lifestyles and prevent diabetes-related complications. This has led to an increased focus on diabetes care in the country, which is driving the demand for diabetes drugs.

Market Restraints

One of the main factors is the high cost of diabetes drugs. Many patients in China may not be able to afford the cost of diabetes drugs, which can limit the growth of the market. In addition, there are concerns about the safety and efficacy of some diabetes drugs, which can also impact the growth of the market.

Another factor that may restrain the growth of the diabetes drugs market in China is the uneven distribution of healthcare resources. While healthcare services in urban areas are generally better developed and more accessible, there are still significant disparities in healthcare access and quality between urban and rural areas. This can limit the growth of the diabetes drugs market in rural areas, where there may be less demand for diabetes drugs.

Competitive Landscape

Key Players

Gan & Lee Pharmaceuticals (CHN)
Tonghua Dongbao Pharmaceutical (CHN)
Jiangsu Hengrui Medicine (CHN)
Humanwell Healthcare Group (CHN)
Shanghai Fosun Pharmaceutical Group (CHN)
Sanofi
Johnson & Johnson
Abott
Bayer Pharmaceuticals
Novo Nordisk
Merck
Eli Lilly and Company
AstraZeneca
Boehringer Ingelheim
Novartis
GlaxoSmithKline

Notable deals

February 2021: Novo Nordisk announced a collaboration with BeiGene to develop and commercialize a glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of diabetes and other metabolic disorders in China. The two companies will work together on the development, manufacturing, and commercialization of the drug.

March 2021: Hua Medicine and Eli Lilly and Company announced a strategic collaboration to develop and commercialize novel diabetes treatments in China. The collaboration will focus on the development of Hua Medicine's lead drug candidate, dorzagliatin, which is a dual-acting glucokinase activator (GKA) that has shown promising results in clinical trials.

August 2021: Jiangsu Hengrui Medicine announced a partnership with Hikma Pharmaceuticals to develop and commercialize insulin products in the Middle East and North Africa region. The partnership includes the manufacturing and supply of insulin products by Jiangsu Hengrui Medicine and the commercialization and distribution of the products by Hikma Pharmaceuticals.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

The regulation of diabetes drugs in China is overseen by the China National Medical Products Administration (NMPA), which is responsible for the approval and registration of all pharmaceutical products in the country. In order for a diabetes drug to be approved for use in China, it must undergo rigorous clinical trials and meet the safety and efficacy standards set by the NMPA.

Diabetes drugs in China are typically covered by the country's National Health Insurance Program, which provides coverage for a wide range of healthcare services and products, including prescription medications. However, the reimbursement rate for diabetes drugs in China can vary depending on a number of factors, such as the drug's cost, its effectiveness, and the patient's individual circumstances.

In 2019, the government announced plans to reduce the prices of 36 commonly used diabetes drugs by an average of 60%. Additionally, the government has also introduced policies aimed at promoting the use of generic diabetes drugs, which are typically less expensive than brand-name drugs. For example, in 2020, the government issued guidelines requiring hospitals to prioritize the use of generic drugs in their procurement processes.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Diabetes Drugs Market Segmentation

By Drug Type (Revenue, USD Bn):

The drug types considered, in this report include Injectable Drugs and Oral Drugs. Injectable drugs are further classified into insulin-based and non-insulin-based injectables. Oral drugs are further classified into various classes as per their mechanism of action as mentioned below :

Injectable Drugs
- Insulin Based Injectables
- Non-insulin Based Injectables
  - Exenatide (Byetta)
  - Dulaglutide (Trulicity)
  - Semaglutide (Ozempic, Wegovy)
  - Liraglutide (`Saxenda, Victoza)
  - Lixisenatide (Adlyxin)
  - Pramlintide (Symlin)
  - Tirzepatide (Mounjaro)
  - Albiglutide (Tanzeum)
Oral Drugs
- Biguanides - Metformin (Glucophage and Glucophase XR)
- Sulfonylureas - Glimepiride (Amaryl), Glyburide (DiaBeta), Glipizide (Glucotrol), Gliclazide (Diamicron), Chlorpropamide (Diabinese)
- Meglitinides and D-Phenylalanine Derivatives - Repaglinide (Prandin), Nateglinide (Starlix)
- Thiazolidinediones (TZDs) - Rosiglitazone (Avandia), Pioglitazone (Actos)
- Dipeptidyl peptidase-IV (DPP-4) inhibitors - Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin (Tradjenta), and Alogliptin (Nesina and Vipidia), Teneligliptin (Tenelia), Vildagliptin (Galvus)
- Alpha-glucosidase Inhibitors - Acarbose (Precose), Miglitol (Glyset), Voglibose (Voglib)
- Sodium-glucose co-transporter-2 (SGLT2) inhibitors - Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), Ertugliflozin (Stelgatro)
- Dopamine D2 agonist – Bromocriptine (Parlodel and Cycloset)
- Glucagon like peptide 1 (GLP-1) receptor agonists - Semaglutide (Rybelsus)
- Bile Acid Sequestrants (BASs) - Colesevelam (Welchol)
- Others (Fixed Dose Combination Drugs)

By Application (Revenue, USD Bn):

Based on application, the market is segmented into Type 1 and Type 2. The 2 types of diabetes drugs are segmented and dominate the market. The Type 2 diabetes segment accounts for the largest sales of the worldwide market a few different kinds. The excessive prevalence of type 2 because of sedentary lifestyles and obesity in all age groups is attributed to the current situation. Around 10% of all diabetes cases are type 1, and approximately 90% of all cases of diabetes in UK are type 2. Hence, it is estimated to the diabetes drugs market will grow across the globe during the forecast period.

Type 1 diabetes (due to β-cell destruction, usually leading to absolute insulin deficiency)
Type 2 diabetes (due to a progressive insulin secretory defect on the background of insulin resistance)
Other diabetes types

By Distribution Channel (Revenue, USD Bn):

Based on distribution channels, the market is classified into hospital pharmacies, rental pharmacies, and online pharmacies. The hospital pharmacies captured the highest market share, owing to the availability of trained & qualified personnel and favorable reimbursement structure. Online pharmacies are estimated to register the highest CAGR in the forecast period, it is attributed to the technological adaptation and acceptance of online pharmacies. Retail pharmacies showed a moderate market share improvement in the healthcare facilities in developing countries is anticipated to propel the popularity of retail pharmacies during the forecast period.

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.